Intellia Therapeutics remains a Buy, driven by two pivotal in vivo gene therapy catalysts: Lonvo-Z for HAE and Nex-Z for ATTR amyloidosis. Lonvo-Z's Phase 3 data met all endpoints with an 87% attack reduction, but market reaction was muted due to safety concerns and the competitive landscape. The FDA lifted clinical holds on Nex-Z Phase 3 trials, enabling advancement in a $16.8bn ATTR market with a differentiated one-time treatment profile.